Three different types of anti-T cell antibody were used in patients undergoing haematopoietic stem cell transplantation (HSCT) with an HLA-A, -B and -DR compatible unrelated donor: ATG-Fresenius (ATG-F) (n = 26), Thymoglobuline (TMG) (n = 61) and OKT-3 (n = 45). The groups were comparable regarding diagnosis, stage, age, conditioning and GVHD prophylaxis, Adverse events were less frequent after ATG-F treatment. Levels of IL-2, IL-6, IFN-␥, TNF-␣ and GM-CSF were increased after OKT-3 infusion. In multivariate analysis OKT-3 treatment (P = 0.01), G-CSF treatment (P = 0.02) and a cell dose у2.7 ؋ 10 8 /kg (P = 0.03) gave a faster engraftment. Acute GVHD grades II-IV occurred in 25% of the ATG-F patients, 12% of the TMGpatients and 43% (P Ͻ 0.001 vs TMG) of the OKT-3 patients. OKT-3 was associated with acute GVHD in multivariate analysis. TRM was 26% using TMG as compared to 43% in the OKT-3 group (P = 0.03). Patient survival at 4 years was 63%, 50% and 45% in the ATG-F, TMG and OKT-3-treated patients, respectively (NS). Relapses were 8%, 49% and 34%, respectively (ATG-F vs TMG, P = 0.03). Relapse-free survivals were 61%, 40% and 37% (NS). Among CML patients the probability of relapse was 61% in TMG-treated patients, while no patients relapsed in the other two groups. To conclude, the type of anti-T cell antibody affects GVHD and relapse after HSCT using unrelated donors.
These problems probably arise because the donors are not as well HLA-matched, especially in minor transplantation antigens. By matching donors carefully using genomic typing and the employment of T cell depletion in vitro or in vivo the results have improved. [5] [6] [7] [8] To reduce the risks of rejection and severe GVHD, recipients of an unrelated stem cell graft receive 5 days of anti-T cell antibody prior to transplant at Huddinge Hospital. We have used three different antibodies: ATG-Fresenius S (ATG-F), Thymoglobuline (TMG) and Orthoclone OKT 3 (OKT-3).
Here we report our results using these three different antibodies.
Materials and methods

Patients
Between May 1988 and June 1998, 145 consecutive patients who received a haematopoietic stem cell transplant (HSCT) from an HLA-A, -B and -DR identical unrelated donor at Huddinge Hospital were treated with anti-T cell antibodies during conditioning. The type of antibody used depended on availability and price. Between 1988 and 1992 we randomly used the antibodies that were commercially available (all three). From 1993 to 1995 Thymoglobuline was more frequently used due to better availability. Due to its lower price, OKT-3 was used more commonly between 1996 and March 1998. Since then we have used Thymoglobuline. The T cell antibodies were given i.v. from day Ϫ5 to day Ϫ1 before transplant. ATG-F was used in 26 patients, Thymoglobuline in 61 patients and OKT-3 in 45. Thirteen patients were switched from one antibody to another due to severe reaction or an insufficient decrease in CD2/CD3-positive cells. This subgroup of patients was omitted. Diagnoses and other patient and donor characteristics are given in Table 1 .
This study was approved by the ethics committee at Huddinge Hospital (349/98).
Donors and tissue typing
HLA-A and -B class I typing was performed serologically using commercially available reagents to define new subgroups. HLA-DR class II antigens were determined employing genomic methods. Initially, the RFLP method was used with the help of cDNA probes to determine DRB,
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M Remberger et al 824 DQA and DQB alleles. 9 Since July 1992, the PCR method, using sequence-specific primer pairs, has been employed to define DRB1-5, DQA1, DQB and DPB1 alleles. 10 As an alternative to bone marrow, 14 patients were given peripheral blood progenitor cells (PBPC) from donors treated with granulocyte colony-stimulating factor (G-CSF).
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Conditioning
One hundred and three patients with a haematological malignancy and eight patients with SAA were given cyclophosphamide (Cy) 60 mg/kg, for 2 days (total dose 120 mg/kg), combined with 10 Gy of total body irradiation (TBI), single fraction, with the lungs shielded to receive no more than 9 Gy. Patients with a metabolic disorder (n = 13) received 4 days of busulphan (Bu), 80 mg/m 2 followed by Cy, 2 g/m 2 , given for 4 days. 12 Three patients with leukaemia and two with SAA received Bu, 4 mg/kg for 4 days (total dose 16 mg/kg), combined with Cy 60 mg/kg for 2 days. Three patients with SAA were given Cy, 60 mg/kg for 2 days, combined with thoraco-abdominal irradiation or total lymphoid irradiation. The protocol has previously been described in detail. 13 
T cell antibodies
All patients were given 1-5 days treatment with anti-T cell antibodies before transplantation, aiming for 5 days. Three different antibodies were used: ATG-Fresenius S (Fresenius AG, Bad Homburg, Germany), Thymoglobuline (Pasteur Mérieux, Lyon, France) and Orthoclone OKT 3 (Ortho Biothech, New Jersey, USA). Prior to the infusion of antibodies, antihistamines and steroids were given. In 97 patients the CD2 and CD3 counts were analysed in blood lymphocytes on the second day of treatment. If the CD3 count was above 30%, the patient was switched to another antibody. This is an arbitrary level. If the CD3 level was above 30% after the first dose a further reduction was not achieved by additional treatment with the same antibody.
GVHD prophylaxis
Most patients (n = 126) were given cyclosporine (CsA) combined with a short course of methotrexate (MTX). MTX was given i.v. at a dose of 15 mg/m 2 on day ϩ1 and 10 mg/m 2 on days 3, 6 and 11 post transplant. 14 Because of anticipated toxicity, MTX was replaced by prednisolone in six patients. CsA i.v. was started on day Ϫ1, dose ranging from 5 to 10 mg/kg/day, with a higher dose given to small children. On the day of HSCT, CsA was lowered to 3-7.5 mg/kg/day. On day ϩ1, or as soon as the patient could take CsA orally, 12.5 mg/kg/day, was given in two doses to adults and a higher dose, 12.5-20 mg/kg/day, to children. During the first month, blood CsA levels were kept at approximately 200-300 ng/ml. 6, 15 After 6 months, the CsA dose was lowered by 25% an alternate months and was discontinued after 12 months in the absence of GVHD. In patients with metabolic disorders, CsA was continued for 24 months. Two different methods for determining CsA blood levels have been used. From 1988 until May 1997, we used the Cyclo-trac SP (Incstar Corporation, MN, USA). Since May 1997, we used the EMIT 2000 Cyclosporine-specific Assay (Behring, Marburg, Germany).
GVHD
Acute GVHD was diagnosed from clinical symptoms and/or biopsies from skin, oral mucosa, liver and gut. GVHD was graded from 0 to IV, according to previously published criteria. 16 At the first sign of grade I GVHD, prednisolone, 2 mg/kg/day, was given to adults and 2-3 mg/kg/day to children, for at least 1 week. Thereafter, the dose was reduced, depending on the response. Some patients with persistent or severe GVHD also received methylprednisolone i.v., ATG or psoralene and ultraviolet light (PUVA). 17 In some patients with recurring GVHD, MTX, 5-10 mg/m 2 , was given once a week. Chronic GVHD was diagnosed from clinical symptoms and/or biopsies from skin, oral mucosa, liver and gut. GVHD was classified as limited or extensive according to previously published criteria. 18 
Cytokines
In 21 patients blood samples for cytokine analysis were drawn 2 h after the anti-T cell antibody was given. Samples were immediately centrifuged and the serum was frozen at Ϫ86°C, until analysis. Serum levels of IL-1␤, IL-2, IL-6, TNF-␣, IFN-␥ and GM-CSF were analysed using the Quantikine ELISA kit from R&D Systems (Minneapolis, MN, USA). Assays were performed according to the manufacturer's instructions.
Antibody titres
From week 1 to week 5 after HSCT, individual serum samples were taken once weekly for analysis of titres of anti-T cell antibodies. These analyses were carried out by Pasteur-Merieux. Ten patients in each of the ATG-F and TMG treatment groups were selected for testing; five with grades II-IV aGVHD and five with grades 0-1 aGVHD.
Supportive care
All patients were kept in reverse isolation, the majority accompanied by a relative who stayed with them in the room. IVIG, 500 mg/kg, was given once before transplantation and once a week during the first 3 months after BMT to 43 patients. Granulocyte transfusions were given to 32 patients with septicaemia and high fever (Ͼ40°C) not responding to antibiotics, or to patients with disseminating or local infections.
The diagnosis of CMV disease required symptoms from the affected organ combined with detection of CMV by histology, isolation or immunohistochemistry in BAL fluid, biopsy material from the gastrointestinal tract, liver biopsies, at autopsy, detection of CMV DNA in cerebrospinal fluid, or typical retinitis changes. 19 The majority of the patients received pre-emptive therapy against CMV with ganciclovir or foscarnet. Before January 1992 a rapid CMV isolation technique was used but since then therapy has been instituted after detection of CMV DNA in two consecutive PCR analyses. 20 Day of engraftment was defined as the first of 3 consecutive days of ANC Ͼ0.5 ϫ 10 9 /l. Sixty-one patients were included in a randomised study, comparing G-CSF, 5 g/kg/day, treatment starting on day 0, ϩ5 or ϩ10 after transplantation (Table 1) .
Statistical analysis
Analysis was performed on 14 November 1998.
The probabilities of GVHD, transplantation-related mortality (TRM), relapse, survival, etc, were calculated according to the Kaplan-Meier product-limit method. 21 In calculating 'current' leukaemia-free survival, patients treated with donor lymphocytes after a relapse and reaching a new remission were considered as disease-free. The differences between two groups were compared with the log-rank test. 22 In comparing CD2/CD3-positive cell counts, cytokine levels, day of engraftment, patient age, etc, the MannWhitney U test was used. For these factors median and range are given. Distributions were compared with the 2 test and corrected with the Yates method. The logistic regression model was used in the risk-factor analysis for acute GVHD and prognostic factors for early engraftment. 23 All patients with grades II-IV acute GVHD or with a survival of at least 30 days without acute GVHD were included in the analysis. In the risk-factor analysis for relapse the Cox regression model was used, 24 including only patients who relapsed or were alive more than 90 days after transplantation. Time from transplant to relapse was calculated using cumulative incidence.
Results
Follow-up, dosing and adjustment
Median follow-up time for surviving patients treated with ATG-F was 73 months (range 10-126), for patients treated with TMG 47 months (6-109) and for those treated with OKT-3, 20 months (6-94).
Most patients received 5 days of antibody treatment. Median dose was 4.9 mg/kg/day (range 3.8-10.3) for ATG-F, 2.3 mg/kg/day (1.7-4.7) for TMG and 5 mg/day (3.5-5) for OKT-3.
The percentage of remaining CD2 ϩ cells was lowest with Adverse events during treatment were more common in patients receiving TMG and OKT-3 as compared to ATG-F (Table 2 ). More severe side-effects such as capillary leakage and respiratory problems were only seen after OKT-3 treatment. The respiratory problems consisted of: dyspnea six, tachypnea and chest pain one each.
Engraftment
Engraftment was seen in 96% of the patients treated with ATG-F, 98% in the group treated with TMG and in 93% of the OKT-3-treated patients. Six (5%) late graft failures or rejections occurred. The median number of days to reach ANC у0.5 ϫ 10 9 /l was 20 for patients treated with ATG-F, 18 (10-32) days for those treated with TMG and 16 (11-27) (P = 0.002 vs ATG-F and P = 0.01 vs TMG) for patients treated with OKT-3. In multivariate analysis treatment with OKT-3 (OR 3.0, CI 1.28-6.89, P = 0.01), G-CSF treatment (OR 2.61, CI 1.20-5.70, P = 0.02) and a nucleated cell dose у2.7 ϫ 10 8 /kg (median) (OR 2.80, CI 1.28-6.11, P = 0.01) were significant factors associated with early engraftment. Factors not significant were PBSC graft, patient age and methotrexate Ͻ4 doses.
Infections
The incidence of bacteraemia was 42%, 53% and 36%, respectively, for patients treated with ATG-F, TMG and OKT-3 (NS). CMV PCR positivity occurred in 38%, 49% and 47% and CMV disease in 8%, 7% and 9% of the three groups (NS).
Cytokines
In serum samples taken 2, 4 and 6 h after anti-T cell antibody treatment, the peak values were found at 2 h. In the 2 h samples, a difference in TNF-␣, IFN-␥, IL-2 and GM- Table 2 Adverse events in different anti-T cell antibodies CSF levels between OKT-3 (n = 6) and ATG (ATG-F or TMG) (n = 15) treatment could be statistically demonstrated ( Figure 1 ). Trend for a difference in IL-6 levels was found. No difference in levels of IL-1␤ was found.
GVHD and TRM
The lowest incidence of acute GVHD grades II-IV was found in patients treated with TMG (12%, CI 5-19%) and the highest in patients treated with OKT-3 (43%, CI 28-58%) (Figure 2 ). More severe GVHD (grades III-IV) occurred in 12% (CI 1-23%) of the patients treated with ATG-F, in none of the patients treated with TMG and in 20% (8-32%) of the OKT-3-treated patients. We found no correlation between the grade of acute GVHD and the levels of CD2 or CD3 on the second day of treatment (r = 0.06 and r = 0.19). Chronic GVHD was seen in 46% (25-67%) and 44% (29-59%) of the ATG-F and TMG-treated patients. Among OKT-3-treated patients the probability of chronic GVHD was 71% (55-87%) (P = 0.02 vs ATG-F and P = 0.005 vs TMG). The transplant-related mortality (TRM) (ie all mortality except relapse) was lowest for TMG-treated patients and highest for OKT-3-treated patients ( Table 3) . Causes of death are presented in Table 4 .
Relapse and survival
The best survival was seen in the ATG-F group and the lowest in the OKT-3 group, but this difference was not statistically significant (Table 3) .
Among patients with malignant disease only one of 18 patients treated with ATG-F relapsed. In the TMG group 19 patients relapsed and among patients treated with OKT-3 six patients relapsed (Table 3) .
In patients with CML, relapse only occurred among patients treated with TMG (Table 3) . Current leukaemiafree survival among CML patients was best for patients receiving ATG-F and lowest for those receiving OKT-3, but this difference was not statistically significant (Table  3 ). In patients with acute leukaemia (AML ϩ ALL), leukaemia-free survival at 3 years was 43% (8-78%), 41% (22-60%) and 36% (16-56%) for ATG-F, TMG and OKT-3-treated patients, respectively (NS). 
Risk factor analysis
In uni-and multivariate analysis the only significant risk factor for acute GVHD grades II-IV was treatment with OKT-3 (OR 3.97, CI 1.72-9.21, P = 0.001). In the risk factor analysis for relapse, treatment with OKT-3 or TMG was of borderline significance in multivariate analysis (RH 6.05, CI 0.82-44.7, P = 0.08) when adjusted for differences in diagnoses. Factors not significant were: diagnosis, age, female donor to male recipient, conditioning, disease stage, sex match, donor/recipient herpes virus serology, stem cell dose, IVIG, acute and chronic GVHD (only for relapse).
Antibody titres
Antibodies could be detected up to 5 weeks after transplantation. Levels were significantly higher in patients treated with ATG-F compared with TMG treated patients (P = 0.02). This correlated with the higher dose used in the ATG-F group (4.9 mg/kg/day vs 2.3 mg/kg/day). There was no difference in antibody levels in patients who developed aGVHD grades II-IV compared to those with grades 0-1.
Discussion
This study includes patients during a 10 year period (1988-1998), but most patients were transplanted after 1990. During this time period there have been no changes in conditioning regimen, GVHD prophylaxis and GVHD treatment that could affect the incidence of relapse or GVHD. There has been improvement in infection prophylaxis, diagnosis and treatment during the period. This may affect the TRM and survival. The fastest engraftment (ANC Ͼ0.5 ϫ 10 9 /l) was seen in patients treated with OKT-3 (on day 16, range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . In this study the early engraftment in this group may be associated with more patients receiving a PBPC graft or treatment with G-CSF after transplantation (Table 1) , both of which are associated with more rapid engraftment. 11, [25] [26] [27] It may also be a result of a greater release of haematopoietic growth factors like GM-CSF and IL-6 found after OKT-3 treatment (Figure Table 4 Causes of death in patients treated with different anti-T cell antibodies 1). The latter idea is supported by the finding that there was no difference in the day of engraftment for patients with or without G-CSF treatment in this group. In multivariate analysis, treatment with OKT-3, G-CSF and high marrow cell dose were significant factors associated with faster engraftment. In a previously published study, early engraftment was a risk factor for acute GVHD in HLA-identical siblings. 28 This may reflect either a more immunologically active graft or high endogenous cytokine release during conditioning or early after transplantation caused by cytotoxic drugs, irradiation or anti-T cell antibodies.
There is now substantial evidence that inappropriate production of inflammatory cytokines such as TNF-␣ is involved in the induction and maintenance of complications like acute GVHD after allogeneic stem cell transplantation. [29] [30] [31] [32] [33] [34] Pre-transplant conditioning results in the release of IL-1 and TNF-␣ by host macrophages. These cytokines activate endothelial cells and induce the expression of HLA and adhesion molecules, which in turn enhance the activation of donor T cells. This will contribute to further macrophage activation by release of IL-2 and IFN-␥. In this study, acute GVHD was more common among patients treated with OKT-3 during pre-transplant conditioning. OKT-3 also resulted in a massive release of inflammatory cytokines, including TNF-␣, 35 which may be involved in the induction of GVHD. This may explain the high incidence of more severe acute GVHD after OKT-3 treatment, as other known risk factors for acute GVHD such as herpes virus status, female donor to male recipient, HLA match and GVHD prophylaxis 28, 36 were similar in patients treated with ATG-F, Thymoglobuline and OKT-3 (Table 1) .
We could not find any correlation between the absolute or relative number of T cells after antibody treatment and the grade of GVHD among the patients. No correlation was expected since the absolute or relative number of T cells present reflects the effect of anti T cell antibodies on host cells (eg rejection), and GVHD is a donor cell effect. Rejection or graft failure was a rare event (5%) in all three groups. More important for GVHD is the in vivo depletion of graft T cells obtained when remaining free anti-T cell antibodies after graft infusion bind to, inactivate or eliminate the T cells in the graft. This may again give a release of inflammatory cytokines that may pave the way for GVHD as mentioned above. We showed that free antibodies could be detected in serum from these patients up to 5 weeks after transplantation. An in vitro test before transplantation, where patient and donor leukocytes are incubated with an anti-T cell antibody and the cytokine release is measured, may be of value to find out which patients need additional GVHD prophylaxis, for instance, treatment with anti-TNF␣ antibodies 37, 38 or IVIG. 39 In patients treated with Thymoglobuline the incidence of acute GVHD уII was low (12%). Since GVHD correlates with the graft-versus-leukaemia (GVL) effect, leukaemia patients in this group had a higher rate of relapse (49%) giving a relapse-free survival of 40%, compared to 61% in patients treated with ATG-F (NS). Among CML patients the high incidence of relapse (61%) may be due to a more effective in vivo T cell depletion of the graft by remaining Thymoglobuline antibodies. It is well known that CML patients given a T cell-depleted graft run a high risk of relapsing. 40, 41 A lower dose, or a shorter course of Thymoglobuline may perhaps give an increase in GVHD and GVL effect, leading to a lower relapse rate and a better relapsefree survival rate for leukaemia patients. For patients with non-malignant disease where a low incidence of GVHD is favourable, a higher dose or more effective antibody is more useful. The results after treatment with ATG-F at a dose of 5 mg/kg for 5 days seem most promising although statistically not proven to be better than the other two groups. An incidence of 25% of GVHD grades II-IV, relapse of 8% and LFS of 61% was achieved. However, these results have to be regarded with caution since the number of patients treated with this antibody is rather low (n = 26). The small number of patients with ALL in the ATG-F group could of course affect the results. However, at our centre there are no differences in relapse rates among patients with ALL, AML or CML transplanted with an unrelated donor. A randomised study between ATG-F and TMG at a lower dose may solve this problem. Another approach may be to undertake a dose descalating study of Thymoglobuline to find out at what dose an acceptable level of acute GVHD, and hopefully optimal relapse rate and relapse-free survival is achieved. In an attempt to achieve more GVL effect to reduce the relapse incidence in patients with malignancies, we are now giving Thymoglobuline for less than 5 days, trying to find the optimal duration and dose of antibody treatment.
To conclude, the type and maybe also dose of anti-T cell antibody during conditioning seems of importance for the outcome after haematopoetic stem cell transplantation from unrelated donors.
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